Natriumchloride Kabipac Fresenius Kabi (Sodium Chloride)

Sodium chloride delivers sodium and chloride ions directly into the bloodstream, raising extracellular sodium concentration and osmolarity. This osmotic effect pulls water into the vascular space, expanding plasma volume and helping maintain normal cellular function and fluid balance.

The dose of Natriumchloride Kabipac is individualized. A qualified prescriber determines the volume and concentration based on the patient’s clinical condition, serum sodium level, and overall fluid requirements.

Safety data for intravenous sodium chloride in pregnancy and lactation are limited. Use is generally considered when the potential benefit outweighs any risk, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Natriumchloride Kabipac is a standard isotonic sodium chloride solution comparable to other 0.9% saline preparations. Its composition, sterility, and EU‑market approval make it suitable for routine fluid replacement, while specific brand formulations may differ in packaging, preservative content, or regulatory status.

The product should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the vial. Before use, inspect for particulate matter or discoloration and follow aseptic techniques when preparing the infusion.

Natriumchloride Kabipac is administered intravenously. The solution is typically diluted in compatible IV fluids or given directly via a controlled infusion pump, with the rate adjusted according to the patient’s fluid status and clinical response.

Serious risks include severe hypernatremia, pulmonary edema, cardiac arrhythmias, and rare anaphylactic reactions. These events are more likely in patients with impaired renal or cardiac function, and they require close monitoring of serum electrolytes and fluid balance.

Patients with known hypersensitivity to sodium chloride solutions, uncontrolled hypernatremia, severe congestive heart failure, or those receiving incompatible hypertonic solutions should not receive Natriumchloride Kabipac unless a clinician determines that benefits outweigh the risks.